Description
Mitochondria-targeted peptide (binds cardiolipin) studied for mitochondrial function, heart failure, and age-related conditions. FDA-approved only as a specific branded product (accelerated approval September 2025) for the narrow indication of Barth syndrome; compounded or general “longevity” use is not covered by that approval.
